



## Objective for Immunotherapy in Gastric Malignant Growth

### Description

The objective of this commentary is to discuss the current state of immunotherapy in gastric cancer and to propose a strategy for its implementation. Gastric cancer is a leading cause of cancer-related death worldwide, and immunotherapy has emerged as a promising treatment option. However, the response rate to immunotherapy is low, and the mechanism of resistance is not fully understood. This commentary will discuss the current state of immunotherapy in gastric cancer and propose a strategy for its implementation. The strategy will focus on the use of immune checkpoint inhibitors (ICIs) in combination with other immunomodulatory agents. This approach is based on the hypothesis that ICIs can overcome the immune tolerance that allows gastric cancer cells to evade the immune system. By combining ICIs with other immunomodulatory agents, it is possible to enhance the immune response and improve the outcome for patients with gastric cancer. This commentary will discuss the current state of immunotherapy in gastric cancer and propose a strategy for its implementation. The strategy will focus on the use of immune checkpoint inhibitors (ICIs) in combination with other immunomodulatory agents. This approach is based on the hypothesis that ICIs can overcome the immune tolerance that allows gastric cancer cells to evade the immune system. By combining ICIs with other immunomodulatory agents, it is possible to enhance the immune response and improve the outcome for patients with gastric cancer.

The objective of this commentary is to discuss the current state of immunotherapy in gastric cancer and to propose a strategy for its implementation. Gastric cancer is a leading cause of cancer-related death worldwide, and immunotherapy has emerged as a promising treatment option. However, the response rate to immunotherapy is low, and the mechanism of resistance is not fully understood. This commentary will discuss the current state of immunotherapy in gastric cancer and propose a strategy for its implementation. The strategy will focus on the use of immune checkpoint inhibitors (ICIs) in combination with other immunomodulatory agents. This approach is based on the hypothesis that ICIs can overcome the immune tolerance that allows gastric cancer cells to evade the immune system. By combining ICIs with other immunomodulatory agents, it is possible to enhance the immune response and improve the outcome for patients with gastric cancer. This commentary will discuss the current state of immunotherapy in gastric cancer and propose a strategy for its implementation. The strategy will focus on the use of immune checkpoint inhibitors (ICIs) in combination with other immunomodulatory agents. This approach is based on the hypothesis that ICIs can overcome the immune tolerance that allows gastric cancer cells to evade the immune system. By combining ICIs with other immunomodulatory agents, it is possible to enhance the immune response and improve the outcome for patients with gastric cancer.

### Acknowledgement

None.

### Conflict of Interest

The author declares no conflict of interest.

---

Fausto Rosa, Department of Gastroenterology, University of Delaware, United States, E-mail: Fausto7766@yahoo.com

Rosa F (2022) Objective for Immunotherapy in Gastric Malignant Growth. J Gastrointest Dig Syst 12:716.

01-November-2022, Manuscript No. JGDS-22-84744;  
03-November-2022, PreQC No. JGDS-22-84744 (PQ);  
17-November-2022, QC No. JGDS-22-84744; 22-November-2022,  
Manuscript No. JGDS-22-84744 (R); 29-November-2022,  
10.4172/2161-069X.1000716

© 2022 Rosa F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.